Plans to list etomidate as illegal drug: Ong Ye Kung, Typhoon Wipha causes major flight disruptions: Singapore live news
Currently, etomidate is listed under the Poisons Act. Under this law, abusers face only a fine. Sellers face possible jail time of up to two years. Ong said this will be done in the coming weeks. He added that it will be an interim measure until further changes can be made to the law to tackle the vaping scourge in Singapore. Read more about why there are plans to list etomidate under the MDA.
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning. Find out more about Typhoon Wipha, which was later downgraded to a severe tropical storm.
Read more in our live blog below, including the latest local and international news and updates:
MOH, MHA working to list etomidate as illegal drug: Ong Ye Kung
Singapore's Health and Home Affairs Ministries are working to list etomidate, which is being abused via e-vaporisers, under the Misuse of Drugs Act (MDA), Health Minister Ong Ye Kung said on Sunday (20 July).
This paves the way for abusers and traffickers of Kpods – vapes containing etomidate – to be treated in the same way as those who abuse or traffic drugs like nimetazepam (Erimin-5), with mandatory rehabilitation and jail time for repeat offenders.
Currently, etomidate is listed under the Poisons Act. Under this law, abusers face only a fine. Sellers face possible jail time of up to two years.
Ong said this will be done in the coming weeks. He added that it will be an interim measure until further changes can be made to the law to tackle the vaping scourge in Singapore.
Read more about why there are plans to list etomidate under the MDA.
Typhoon Wipha causes damage, disrupt flights, before weakening to severe tropical storm
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning.
Airports in Hong Kong, Shenzhen, Zhuhai and the casino hub of Macao canceled or postponed flights for most of the day, according to their websites. Hong Kong grounded at least 400 flights, affecting around 80,000 passengers, broadcaster RTHK said. Some high-speed train services were also suspended.
The typhoon stayed just offshore until about 6 pm, when it made landfall in a coastal area of Taishan city in Guangdong province, China's National Meteorological Center said. It then weakened to a severe tropical storm with maximum sustained winds of 108 kph.
Singapore's Health and Home Affairs Ministries are working to list etomidate, which is being abused via e-vaporisers, under the Misuse of Drugs Act (MDA), Health Minister Ong Ye Kung said on Sunday (20 July).
This paves the way for abusers and traffickers of Kpods – vapes containing etomidate – to be treated in the same way as those who abuse or traffic drugs like nimetazepam (Erimin-5), with mandatory rehabilitation and jail time for repeat offenders.
Currently, etomidate is listed under the Poisons Act. Under this law, abusers face only a fine. Sellers face possible jail time of up to two years.
Ong said this will be done in the coming weeks. He added that it will be an interim measure until further changes can be made to the law to tackle the vaping scourge in Singapore.
Read more about why there are plans to list etomidate under the MDA.
Typhoon Wipha causes damage, disrupt flights, before weakening to severe tropical storm
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning.
Airports in Hong Kong, Shenzhen, Zhuhai and the casino hub of Macao canceled or postponed flights for most of the day, according to their websites. Hong Kong grounded at least 400 flights, affecting around 80,000 passengers, broadcaster RTHK said. Some high-speed train services were also suspended.
The typhoon stayed just offshore until about 6 pm, when it made landfall in a coastal area of Taishan city in Guangdong province, China's National Meteorological Center said. It then weakened to a severe tropical storm with maximum sustained winds of 108 kph.
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning.
Airports in Hong Kong, Shenzhen, Zhuhai and the casino hub of Macao canceled or postponed flights for most of the day, according to their websites. Hong Kong grounded at least 400 flights, affecting around 80,000 passengers, broadcaster RTHK said. Some high-speed train services were also suspended.
The typhoon stayed just offshore until about 6 pm, when it made landfall in a coastal area of Taishan city in Guangdong province, China's National Meteorological Center said. It then weakened to a severe tropical storm with maximum sustained winds of 108 kph.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Respiree Closes US$11.6M Series A Financing Round Led by We Venture Capital and ClavystBio
HOUSTON and SINGAPORE, July 23, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, announced the successful closing of a US$11.6 million Series A financing round led by We Venture Capital and ClavystBio. The round also had participation from Adaptive Capital Partners, conversion of note securities from Mayo Clinic's Mayo Foundation for Medical Research and from existing investors including Greenwillow Capital Management, Seeds Capital, and she1K angel investment. Proceeds will support expansion of Respiree's commercial team and U.S. presence, including company headquarters in Houston, Texas, at the Texas Medical Center (TMC) Respiree, with Founder and Chief Executive Officer Dr. Gurpreet Singh at Center 'The digitalization of healthcare offers a powerful opportunity to improve outcomes and efficiency—but without the right tools, it risks overwhelming care systems, especially amid workforce shortages,' said Dr. Gurpreet Singh, Founder and CEO of Respiree. 'What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality. We're now focused on scaling these tools to enhance the entire patient journey—from smarter triage to follow-up.' Respiree's innovative, augmented-AI platform seeks to support quicker, efficient and precise decision making in various healthcare settings by automating patient monitoring, care pathway management and clinical insight delivery. One of its flagship AI models developed during the Mayo Clinic Platform_Accelerate program, where Respiree graduated from, can help healthcare professionals detect patient deterioration earlier – including rapid response calls in general wards and unplanned ICU transfers. Published as a pre-print in The Lancet, this flagship AI model significantly reduced false alarms while maintaining strong sensitivity — outperforming the positive predictive value (PPV) of EPIC's deterioration index by a factor of six (54.9% vs 8%). Respiree is currently in the process of seeking clearance from the US Food and Drug Administration (FDA) for its flagship AI model. The goal is to integrate the model into its platform, 1Bio™, which already incorporates data from electronic health records (EHRs), mobile questionnaires, third party devices and Respiree's proprietary, U.S.-patented, FDA-cleared sensors to provide longitudinal insights into disease trajectories. 'We are very proud to welcome Respiree to the We VC portfolio,' said Louise Warme, Head of We Venture Capital. 'Respiree stands out in the market by providing a patient monitoring AI/ML + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration. Their scientifically validated data and key partnerships position Respiree for a promising scale-up journey driven by an extremely execution-focused team.' 'ClavystBio's investment in Respiree is central to our strategy of helping companies scale globally from and through Singapore. Their innovative AI-powered monitoring platform is set to enhance patient care and empower clinical teams with actionable insights. This further underscores our commitment to accelerating medtech innovations aimed at improving patient outcomes across care settings,' said Anselm Tan, Digital Health & MedTech Lead, ClavystBio. Respiree's current solutions include: Scalable AI modules designed to be device-agnostic, platform independent and EHR-compatible, with increased precision to identify patient deterioration across patient touchpoints with low false alarms Pathway-management modules designed to automate delivery of standardized care pathways and requirements for nurses and patients to execute Centralized, EHR-agnostic platform connected to a broad range of EHR environments and medical device systems, consolidating continuous real-time analytics and data from multiple sources Connected wearables with configurable acquisition settings for a range of use-cases, capable of capturing a broad range of cardio-respiratory measures 'Respiree has achieved much since Greenwillow Capital Management first invested in February 2022 and continued to support the Company in the convertible notes last year. We are incredibly encouraged by the commercialization of Respiree's products and services in tier-one markets and look forward to being part of Respiree's growth as it continues to transform patient care on a global scale. We very much welcome the new investors We VC, ClavystBio and Adaptive Capital and look forward to working together in Respiree's forward journey,' said Dr. Wong Mun Yew, Managing Partner of Oriza Greenwillow Technology Fund. Founded in Singapore, Respiree is now executing its global strategy to expand into new markets worldwide. Respiree's solutions are currently available in the U.S., Australia, and across Asia-Pacific (APAC). The company recently announced a partnership with Roche Diagnostics to launch pilot programs across the APAC region. The company has also established key international partnerships with leading global healthcare providers to support its expansion across both acute and home healthcare settings. A portion of the Series A funds will be used to strengthen operations with existing channel partners and accelerate the development of new business relationships. Respiree plans to expand its offerings into newer international markets including the Gulf Cooperation Council and Thailand. About RespireeRespiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare's care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). ( About We Venture CapitalWe Venture Capital is a specialized fund, investing globally in diagnostics start-ups, as well as digital solutions and life science tools disrupting diagnostics. Launched 2023, We VC is focused on Series A investments, but also invest Seed and Series B. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare. About ClavystBio ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. ( About Greenwillow Capital Management The Oriza Greenwillow Technology Fund is a venture capital fund established jointly by Greenwillow Capital Management Pte Ltd, an MAS-licensed fund management company based in Singapore, and Oriza Holdings, an investment firm from China with assets under management exceeding RMB120 billion. The Fund invests in early-stage technology start-ups in Singapore and the fast-growing markets of Southeast Asia, with a primary focus on the smart cities and health-tech sectors. For more information, please visit Press ContactCammy DuongLifeSci Communicationscduong@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Chinese actor Zhang Yiyang reportedly executed for murder of teen
Chinese actor and singer Zhang Yiyang was reportedly executed last year for murdering a teenager in 2022. He is the first known entertainer in mainland China to be executed for such a crime, Channel News Asia reported. According to records from the Intermediate People's Court of Xianyang City in Shaanxi province, Zhang, then 30, lured the 16-year-old girl into a remote forest near Xingping City under the pretence of a birthday celebration on 26 February 2022. They had a dispute and Zhang attacked her with a folding knife, killing her. Zhang allegedly attempted to conceal his crime by disposing of his clothes and the victim's phone in a reservoir and then checked into a hotel intending to take his own life. Hotel staff intervened and alerted authorities, who arrested him soon afterwards. Zhang had started dating the victim in September 2021, according to The Standard, and reportedly coerced her to stay in the relationship when she wanted to break up. A local court handed down the death sentence to Zhang which he appealed. The sentence was upheld, however, and the actor was executed about six months later on 18 December 2024, Channel News Asia reported, citing court statements. After local media began reporting on Zhang's case, commentators on social media platforms such as Weibo and Douban expressed both anger and shock at the brutality of the crime and the lack of a formal industry response. In particular, commentators were upset with the entertainment industry for the continued availability of Zhang's works, including The Sound of Music, a film also known as Jieyou Sound Hall which premiered in March 2025. Zhang, unlike other celebrities implicated in misconduct, has not been added to China's official 'bad artist' blacklist nor have his works been removed from streaming platforms. Zhang, born 1 May 1990 in Xingping, started his career by appearing on a reality TV show in 2012 and went on to release songs such as 'I Only Care About People Who Care About Me' and 'Crying Man' and hold minor acting roles in webseries and low‑profile TV shows.
Fox News
3 hours ago
- Fox News
Is America Ready For War In The Indo-Pacific?
The President of the Philippines was at the White House on Tuesday visiting President Trump, discussing the issue of China and their ambitions to expand. U.S. lawmakers have asked the Defense Department to study building a joint munitions hub in the Philippines, as China continues to menace other nations crossing through the South China Sea. When it comes to American military spending, we are on track to allocate more than $920 billion in the next fiscal year, and it appears there's bipartisan support to fully fund this Pacific Deterrence Initiative. Florida Republican Senator Rick Scott sits on the Armed Services and Homeland Security Committee, and he joined the Rundown to discuss the long-term threats posed by both China and Iran. The CDC reports an estimated 48,422 deaths from synthetic opioids, mostly fentanyl, in 2024. With a dangerous amount of the drug supply now laced with this deadly substance, overdose deaths are surging, especially among young people. President Trump recently signed the Halt Fentanyl Act, expanding law enforcement's ability to crack down on traffickers. Gregory Swan, who lost his son Drew to a fentanyl overdose in 2013, co-founded Fentanyl Fathers to raise awareness and prevent more families from suffering the same loss. He joins the Rundown to discuss his mission: educating students, empowering parents, and mobilizing a movement to fight the fentanyl crisis. Plus, commentary from FOX News Digital columnist David Marcus. Photo Credit: AP Learn more about your ad choices. Visit
